
|Videos|January 16, 2014
Treating NSCLC With Nintedanib
Author(s)Chandra P. Belani, MD
Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Advertisement
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).
Clinical Pearls:
- Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC
- This study showed an improvement in progression-free survival
- In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















